Mira Pharmaceuticals Inc (MIRA)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$0.76+3.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · MIRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 11 industry peers · Company calendar date is not available
MIRA — litigation filed
Dated 2026-09-01
Regulation FD Disclosure. On September 1, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55, the Company’s investigational oral, non-opioid drug candidate being developed for inflammatory pain. The results are expected to inform dose selection for the next phase of the Company’s ongoing IND-enabling program. Subject to successful completion of the remaining…
Why it matters: Getting exclusive rights would help MIRA grow and prove its plan works.
Supportive ifA press release confirming exclusive rights for MIRA-55 and SKNY-1.
Worry ifNo announcement or failure to secure rights for MIRA-55 and SKNY-1.
Why it matters: Recent agreements expand MIRA's rights and could boost growth. Delays or failures could hurt prospects.
Supportive ifA press release confirms more successful M&A deals or partnerships.
Worry ifThere are no new updates or bad news about the recent M&A activities.
Why it matters: Managing the CFO transition well is key for financial stability. It may affect investor trust.
Worry ifMIRA gives a positive update on the CFO transition.
Less concerning ifMIRA reports more issues or delays in the CFO transition.
Why it matters: Moving SKNY-1 to GLP studies shows progress in treating obesity.
Supportive ifA press release says SKNY-1 has started GLP toxicology studies.
Worry ifNo news on progress toward GLP toxicology studies in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$208 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $670 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,589 loss on $10,000 · 65.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If successful, Ketamir-2 could help treat nerve pain from chemotherapy.
Supportive ifMIRA sends Phase 2a protocol documents to the FDA for Ketamir-2.
Worry ifMIRA delays or fails to submit the Phase 2a protocol to the FDA.
Why it matters: If SKNY-1 moves to clinical trials, it could signal a new treatment option for obesity and addiction. This would enhance MIRA's portfolio.
Supportive ifSKNY-1 is now in Phase 1 trials for obesity and addiction.
Worry ifNo updates on SKNY-1 moving to clinical trials by the end of the year.
Why it matters: News on the CFO change may show stability in management and finances.
Watch forAn announcement about a new CFO or updates on the transition.
Also watch forNo updates or further delays in appointing a new CFO.
Why it matters: Good results would help MIRA-55 become a non-opioid treatment for chronic pain.
Supportive ifMIRA-55 has good oral bioavailability. It spreads well in brain and liver tissues.
Worry ifMIRA-55 does not show key benefits in upcoming studies.
Why it matters: The IND submission is a key step toward human trials for MIRA-55. It shows progress in developing a non-opioid therapy for inflammatory pain.
Supportive ifMIRA submits the IND application for MIRA-55 to the FDA by the end of Q1 2027.
Worry ifMIRA delays the IND submission beyond Q1 2027.
Why it matters: More toxicology results will show how safe and effective MIRA-55 is. Good results may help investors feel more confident.
Supportive ifMIRA shares good results from the next phase of toxicology studies for MIRA-55.
Worry ifMIRA has bad results or issues in the toxicology studies for MIRA-55.